X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA TORRENT PHARMA ALEMBIC PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 24.2 44.3 54.7% View Chart
P/BV x 6.8 6.3 108.4% View Chart
Dividend Yield % 0.7 0.8 84.8%  

Financials

 ALEMBIC PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
TORRENT PHARMA
Mar-18
ALEMBIC PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs7921,550 51.1%   
Low Rs4431,144 38.7%   
Sales per share (Unadj.) Rs167.0354.7 47.1%  
Earnings per share (Unadj.) Rs38.240.1 95.2%  
Cash flow per share (Unadj.) Rs42.064.2 65.4%  
Dividends per share (Unadj.) Rs4.0014.00 28.6%  
Dividend yield (eoy) %0.61.0 62.3%  
Book value per share (Unadj.) Rs84.9273.1 31.1%  
Shares outstanding (eoy) m188.52169.22 111.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.8 97.3%   
Avg P/E ratio x16.233.6 48.1%  
P/CF ratio (eoy) x14.721.0 70.1%  
Price / Book Value ratio x7.34.9 147.5%  
Dividend payout %10.534.9 30.0%   
Avg Mkt Cap Rs m116,383227,897 51.1%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m4,21411,353 37.1%   
Avg. sales/employee Rs ThNM4,083.0-  
Avg. wages/employee Rs ThNM772.3-  
Avg. net profit/employee Rs ThNM461.3-  
INCOME DATA
Net Sales Rs m31,48760,021 52.5%  
Other income Rs m552,988 1.8%   
Total revenues Rs m31,54263,009 50.1%   
Gross profit Rs m10,06013,493 74.6%  
Depreciation Rs m7224,086 17.7%   
Interest Rs m373,085 1.2%   
Profit before tax Rs m9,3569,310 100.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1602,529 85.4%   
Profit after tax Rs m7,1946,781 106.1%  
Gross profit margin %31.922.5 142.1%  
Effective tax rate %23.127.2 85.0%   
Net profit margin %22.811.3 202.2%  
BALANCE SHEET DATA
Current assets Rs m15,06652,623 28.6%   
Current liabilities Rs m7,67452,022 14.8%   
Net working cap to sales %23.51.0 2,342.4%  
Current ratio x2.01.0 194.1%  
Inventory Days Days67120 56.0%  
Debtors Days Days4176 53.3%  
Net fixed assets Rs m8,23785,016 9.7%   
Share capital Rs m377846 44.6%   
"Free" reserves Rs m15,41645,376 34.0%   
Net worth Rs m16,00546,222 34.6%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m24,594142,432 17.3%  
Interest coverage x255.24.0 6,352.3%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.30.4 303.8%   
Return on assets %29.46.9 424.5%  
Return on equity %44.914.7 306.4%  
Return on capital %58.714.2 413.4%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81114,580 122.2%   
Fx outflow Rs m5,3183,600 147.7%   
Net fx Rs m12,49310,980 113.8%   
CASH FLOW
From Operations Rs m9,3048,942 104.0%  
From Investments Rs m-3,105-47,070 6.6%  
From Financial Activity Rs m-1,95934,174 -5.7%  
Net Cashflow Rs m4,240-3,655 -116.0%  

Share Holding

Indian Promoters % 74.1 71.5 103.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 7.0 41.3%  
FIIs % 9.1 12.6 72.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 8.8 158.0%  
Shareholders   49,328 26,511 186.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Up Over 240 Points; Rupee Touches Record Low(12:30 pm)

After opening the day in the green, stock markets in India have continued their momentum and are presently trading on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)

Aug 1, 2018

Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)

Aug 1, 2018

PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 14, 2018 02:05 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS